开发和描述含有克林达米辛的德克斯水凝,用于控制药物释放和抑制病原体
Iqra Jawad1, Asma Rehman1, Mariam Hamdan2
1Industrial Biotechnology Division, National Institute for Biotechnology and Genetic Engineering College, Pakistan Institute of Engineering and Applied Sciences (NIBGE-C, PIEAS), Faisalabad 38000, Pakistan.
Gels (Basel, Switzerland)
|January 27, 2026
概括
这项研究开发了一种德克斯水凝,用于控制克林达米辛的输送. 这种生物相容的水凝显示出出色的膨胀,稳定性和病原体抑制性质,使其成为药物输送应用的前景.
科学领域:
- 生物材料科学 生物材料科学
- 聚合物化学 聚合物化学
- 药物输送系统 药物输送系统
背景情况:
- 德克斯是一种天然,生物相容,可生物降解的聚合物,非常适合用于凝配方.
- 水凝具有医疗应用的理想特性,包括药物输送和组织工程.
- 控制的药物输送系统旨在提高治疗疗效和患者的遵守性.
研究的目的:
- 为了合成和表征克林达米辛封装的德克斯水凝.
- 为了评估水凝的膨胀行为,pH和温度的依赖性以及稳定性.
- 评估克林达米辛载荷水凝的药物载荷能力,体外药物释放和抗菌活性.
主要方法:
- 通过一种成本效益高的方法合成德克斯水凝.
- 胀比率的表征,pH/温度的依赖性,以及表面形态 (SEM).
- 在体外释放药物的研究和针对 Staphylococcus gallinarium 和 Bacillus subtilis 的抗菌分析.
主要成果:
- 水凝在25°C的水中在120分钟内出现最大膨胀 (73±1%).
- 胀行为依赖于pH值和温度,表明有针对性交付的潜力.
- 观察到高药载荷 (70 ± 2%),快速体外释放 (65 ± 2%) 和显著的病原体抑制活性.
结论:
- 合成的德克斯水凝是一种有前途的生物材料,用于控制克林达米辛的输送.
- 水凝的特性支持其在先进的药物输送系统中使用.
- 该材料证明了对特定细菌病原体的有效性.
相关概念视频
01:10In Vitro Drug Release Testing: Overview, Development and Validation
327
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
327
01:28Load-frequency control
661
Load-frequency control (LFC) is vital for maintaining power system stability, ensuring that frequency and power flows remain within acceptable limits during load changes. Turbine-governor control eliminates rotor accelerations and decelerations following load changes. However, a steady-state frequency error persists when the change in the turbine-governor reference setting is zero. In an interconnected power system, each area agrees to export or import a scheduled amount of power through...
661
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.6K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.6K
00:46Feedback Inhibition
57.1K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.1K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
886
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
886
01:03Drug Control Governance: Regulatory Bodies and Their Impact
534
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
534